2024年,《Journal for ImmunoTherapy of Cancer》杂志发表了题为《Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase Ⅱ CheckM...
2. Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair deficient/microsatellite instability-high colorectal cancer (CheckMate 142): results of an open-label, multicenter, phase 2 ...
参考文献: [1] Lenz HJ, Cutsem EV, Limon ML, et al. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. J Clin Oncol. October 12, 2021. DOI: 10.1200/JCO.21.01015. [2]Bras...
[1] Lenz HJ, Cutsem EV, Limon ML, et al. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. J Clin Oncol. October 12, 2021. DOI: 10.1200/JCO.21.01015. [2]Brastianos, P...
CheckMate142:Nivo+/-Ipi治疗dMMR转移性结直肠癌 摘要553（联合）12m-PFS率71% 摘要553（联合）12m-OS率85% 摘要554（单药）12m-PFS率44% 摘要554（单药）12m-OS率72% 2018ASCOGI CheckMate142:Nivo+/-Ipi治疗dMMR转移性结直肠癌 2018ESMO CheckMate142:Nivo+低剂量Ipi组一线治疗的RR可达60% 2018ESMO Chec...
Impact of viral aetiology in the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma(HIMALAYA研究中,度伐利尤单抗联合曲美木单抗治疗不可切除肝细胞癌的病毒病因影响) 这项探索性分析评估了在III期 HIMALAYA研究中,对患有不可切除肝细胞癌(uHCC)的参与者,根据乙型肝炎...
A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142) anti-programmed death-1, immunotherapy, nivolumab, non-small cell lung cancerProgress in the treatment of patients with advanced stage squamous cell non-smal... BM Squibb 被引量: 5发表: ...
In the phase 2, non-randomised CheckMate 142 study, nivolumab, a PD-1 inhibitor, plus ipilimumab, a cytotoxic T-lymphocyte antigen 4 inhibitor, showed promising efficacy, including long-term survival benefit, and manageable safety in previously treated and untreated immunotherapy-naive patients with ...
Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary.
2. A study of nivolumab, nivolumab plus ipilimumab, or investigator's choice chemotherapy for the treatment of participants with deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC) (CheckMate 8HW). ClinicalTrials.gov. Updated October 27, 2023...